

**PREMATURE MORTALITY FROM
CARDIOVASCULAR DISEASE: GLOBAL
BURDEN AND COUNTRY-SPECIFIC ESTIMATE
THROUGH REVIEW STUDY, TREND ANALYSIS,
PREDICTION MODELLING, AND CAUSAL
INFERENCE STUDY**

WAN SHAKIRA BINTI RODZLAN HASANI

UNIVERSITI SAINS MALAYSIA

2024

**PREMATURE MORTALITY FROM
CARDIOVASCULAR DISEASE: GLOBAL
BURDEN AND COUNTRY-SPECIFIC ESTIMATE
THROUGH REVIEW STUDY, TREND ANALYSIS,
PREDICTION MODELLING, AND CAUSAL
INFERENCE STUDY**

by

WAN SHAKIRA BINTI RODZLAN HASANI

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

DECEMBER 2024

ACKNOWLEDGEMENT

I extend my deepest gratitude to my main supervisor, Professor Dr. Kamarul Imran Musa, for his invaluable academic support, guidance, and encouragement throughout the entirety of this PhD journey. His flexibility, constructive feedback, and understanding have made my PhD experience smooth. I am truly grateful for his brilliant ideas in designing my thesis. My heartfelt appreciation also goes to my co-supervisor, Associate Professor Dr. Yee Cheng Kueh, for their consistent and dedicated efforts in reviewing every page of this thesis and draft manuscripts. I would like to express my gratitude to the Ministry of Health Malaysia for providing full-time study leave and scholarship, which made this journey possible. Special thanks to my research team members from the National Institutes of Health, Ministry of Health Malaysia, especially Datuk Dr. Nor Asiah Muhamad and Dr. Azahadi Omar, as well as the team from the Institute for Public Health (Dr Noor Ani Ahmad, Dr Muhammad Fadhli and Dr Shubash Shander). I am deeply indebted to Dr. Tengku Muhammad Hanis, my senior PhD coursemate, whose guidance, particularly in the analysis part, from the beginning of the PhD journey until the end. I have learned a lot from him. To my parents (Rodzlan Hasani Muhammed and Wan Sharipah Nik Sof), thank you for your immense support, understanding, and never-ending dua throughout my journey. To my beloved husband, Mohd Azamli, thank you for your unwavering support. Your presence has made this three-year journey delightful, wonderful, and filled with happiness. To my son, Thalhah, you have been my source of strength and positivity. Despite the recent diagnosis of a genetic disorder, you remain my special child, and I will forever cherish you. You are undeniably a precious gift from Allah.

TABLE OF CONTENTS

| | |
|---|--------------|
| ACKNOWLEDGEMENT | ii |
| TABLE OF CONTENTS..... | iii |
| LIST OF TABLES | xi |
| LIST OF FIGURES | xv |
| LIST OF SYMBOLS | xix |
| LIST OF ABBREVIATIONS | xx |
| LIST OF APPENDICES | xxiii |
| ABSTRAK | xxiv |
| ABSTRACT | xxvii |
| CHAPTER 1 INTRODUCTION..... | 1 |
| 1.1 Background of the study | 1 |
| 1.2 Problem statement | 3 |
| 1.3 Research questions | 7 |
| 1.4 Research objectives | 8 |
| 1.4.1 General objective..... | 8 |
| 1.4.2 Specific objectives..... | 8 |
| 1.5 Overview of studies..... | 9 |
| 1.5.1 Study 1: Bibliometric analysis on premature CVD mortality | 10 |
| 1.5.2 Study 2a: Systematic review on years of life lost from CVD mortality | 10 |
| 1.5.3 Study 2b: Meta analysis of ASMR from premature CVD Mortality..... | 11 |
| 1.5.4 Study 3: Trend of ASMR from CVD in Malaysia | 11 |
| 1.5.5 Study 4: Prognostic Factors for Premature CVD Mortality in Malaysia | 12 |
| 1.5.6 Study 5: Constructing DAG model for Premature CVD Mortality..... | 13 |

| | |
|---|-----------|
| CHAPTER 2 LITERATURE REVIEW..... | 14 |
| 2.1 Introduction | 14 |
| 2.2 Cardiovascular diseases..... | 14 |
| 2.2.1 Definition CVD | 14 |
| 2.2.2 Main type of CVD..... | 15 |
| 2.2.2(a) Ischemic heart disease | 15 |
| 2.2.2(b) Stroke..... | 16 |
| 2.2.3 Classification of CVD (codes) | 17 |
| 2.2.4 Epidemiology of CVD | 19 |
| 2.2.4(a) Incidence, burden, and trend of CVD | 19 |
| 2.2.4(b) The global burden of IHD..... | 19 |
| 2.2.4(c) The global burden of stroke..... | 20 |
| 2.2.4(d) Epidemiological transitions | 20 |
| 2.3 Premature mortality..... | 20 |
| 2.3.1 Definition | 20 |
| 2.3.2 Years of life lost | 21 |
| 2.3.3 Age standardized mortality rate | 22 |
| 2.3.4 Global burden of Premature CVD mortality | 24 |
| 2.3.5 Country specific burden of premature CVD mortality..... | 25 |
| 2.4 CVD mortality risk factors..... | 26 |
| 2.4.1 Non-modifiable risk factors | 26 |
| 2.4.2 Modifiable risk factors | 29 |
| 2.4.3 Social determinants of health | 35 |
| 2.5 CVD risk prediction models..... | 37 |
| 2.6 Review methodologies | 38 |
| 2.6.1 Bibliometric analysis..... | 39 |
| 2.6.2 Systematic review and meta-analysis..... | 41 |

| | | |
|------------------|---|-----------|
| 2.6.3 | Comparison three type of review studies | 44 |
| 2.7 | Trend analysis | 45 |
| 2.7.1 | Definition and type of trend analysis | 45 |
| 2.7.2 | Joinpoint regression..... | 46 |
| 2.8 | Survival modelling study | 48 |
| 2.8.1 | Types of survival analysis | 49 |
| 2.8.1(a) | Non-parametric survival analysis | 50 |
| 2.8.1(b) | Semi-parametric survival analysis..... | 51 |
| 2.8.1(c) | Parametric survival analysis | 52 |
| 2.8.2 | Imbalanced data, survival modeling, and resampling techniques..... | 55 |
| 2.9 | Causal inference | 56 |
| 2.9.1 | Causal inference overview | 56 |
| 2.9.2 | Directed acyclic graph (DAG) | 58 |
| 2.9.3 | Causal inference framework..... | 63 |
| 2.10 | Delphi Method..... | 65 |
| 2.10.1 | Delphi Method overview..... | 65 |
| 2.10.2 | Fuzzy Delphi Method..... | 65 |
| CHAPTER 3 | METHODOLOGY | 67 |
| 3.1 | Introduction | 67 |
| 3.2 | Study 1: Bibliometric Analysis of Premature Mortality | 69 |
| 3.2.1 | Data source and literature inclusion criteria..... | 69 |
| 3.2.2 | Data extraction and collection..... | 70 |
| 3.2.3 | Data analysis and software | 71 |
| 3.3 | Study 2a: Systematic review of YLL of premature CVD mortality | 73 |
| 3.3.1 | Study protocol | 73 |
| 3.3.2 | Search strategy | 73 |
| 3.3.3 | Study selection | 76 |

| | | |
|----------|--|-----|
| 3.3.4 | Data extraction and management | 79 |
| 3.3.5 | Quality assessment | 80 |
| 3.3.6 | Research team (screening and data extraction) | 81 |
| 3.4 | Study 2b: Meta-analysis of ASMR for Premature CVD Mortality | 85 |
| 3.4.1 | Protocol and registration | 85 |
| 3.4.2 | Search strategy | 85 |
| 3.4.3 | Inclusion and exclusion criteria..... | 90 |
| 3.4.4 | Screening process..... | 90 |
| 3.4.5 | Data extraction and management | 91 |
| 3.4.6 | Quality assessment | 92 |
| 3.4.7 | Statistical Analysis | 95 |
| 3.4.8 | Assessment of heterogeneity | 97 |
| 3.4.9 | Assessment of reporting biases | 97 |
| 3.4.10 | Sensitivity analysis..... | 98 |
| 3.4.11 | Research team (screening and data extraction) | 99 |
| 3.5 | Study 3: Trend of ASMR from CVD in Malaysia | 100 |
| 3.5.1 | Study design and target population | 100 |
| 3.5.2 | Source of data..... | 100 |
| 3.5.3 | Statistical analysis | 101 |
| 3.5.3(a) | Age standardized mortality rate calculation | 101 |
| 3.5.3(b) | Joinpoint regression analysis | 102 |
| 3.5.4 | Data source approval..... | 105 |
| 3.6 | Study 4: Prognostic factors for premature CVD mortality in Malaysia..... | 105 |
| 3.6.1 | Study design and subjects | 106 |
| 3.6.2 | Data sources | 107 |
| 3.6.3 | Baseline data collection..... | 107 |
| 3.6.4 | Definition of terms and study variables | 108 |

| | |
|---|------------|
| 3.6.4(a) Outcome variable..... | 108 |
| 3.6.4(b) Prognostic variables..... | 108 |
| 3.6.5 Sample size calculation | 113 |
| 3.6.6 Statistical analyses..... | 116 |
| 3.6.6(a) Incidence rate..... | 116 |
| 3.6.6(b) Semi-parametric survival analysis | 120 |
| 3.6.6(c) Parametric survival analysis | 121 |
| 3.6.6(d) Sensitivity analysis | 124 |
| 3.7 Study 5: Constructing Causal Pathways for Premature CVD Mortality | 125 |
| 3.7.1 Overview study stage | 125 |
| 3.7.2 Stage 1: Evidence synthesis for constructing DAGs (ESC-DAG)..... | 128 |
| 3.7.3 Stage 2: Delphi method for expert consensus | 130 |
| 3.7.3(a) First round interview..... | 130 |
| 3.7.3(b) Second round interview | 130 |
| 3.7.3(c) Fuzzy Delphi method..... | 131 |
| 3.7.4 Stage 3: Testing DAG model with available data | 134 |
| 3.8 Ethical approval..... | 136 |
| CHAPTER 4 RESULTS AND DISCUSSION..... | 137 |
| 4.1 Introduction | 137 |
| 4.2 Study 1: Bibliometric Analysis of Premature Mortality | 137 |
| 4.2.1 Results | 137 |
| 4.2.1(a) Publication by year | 138 |
| 4.2.1(b) Publication by country | 139 |
| 4.2.1(c) Publication by journal | 141 |
| 4.2.1(d) Publication by authors | 142 |
| 4.2.1(e) Keywords analysis | 144 |
| 4.2.2 Discussion | 151 |

| | | |
|----------|---|-----|
| 4.2.3 | Strengths and limitations | 155 |
| 4.3 | Study 2a: Systematic review of YLL of premature CVD mortality | 156 |
| 4.3.1 | Results | 156 |
| 4.3.1(a) | Quality assessment..... | 156 |
| 4.3.1(b) | Characteristic of included studies..... | 156 |
| 4.3.1(c) | Years of potential life lost (YPLL) from CVD..... | 165 |
| 4.3.1(d) | Standard expected years of life lost (SEYLL) from CVD..... | 168 |
| 4.3.1(e) | The pattern of years of life lost from CVD..... | 171 |
| 4.3.2 | Discussion | 176 |
| 4.3.3 | Strengths and limitations | 179 |
| 4.4 | Study 2b: Meta-analysis of ASMR for premature CVD mortality | 181 |
| 4.4.1 | Results | 181 |
| 4.4.1(a) | Study characteristics | 181 |
| 4.4.1(b) | Quality assessment..... | 186 |
| 4.4.1(c) | Overall ASMR estimates | 186 |
| 4.4.1(d) | Subgroup analysis by CVD types | 187 |
| 4.4.1(e) | Subgroup analysis by sex..... | 189 |
| 4.4.1(f) | Subgroup analysis by income country level | 194 |
| 4.4.1(g) | Subgroup analysis by study time | 197 |
| 4.4.1(h) | Sensitivity analysis – removing outliers | 201 |
| 4.4.1(i) | Sensitivity analysis – stratified by age thresholds | 204 |
| 4.4.1(j) | Meta-regression model | 206 |
| 4.4.1(k) | Publication's bias..... | 207 |
| 4.4.2 | Discussion | 208 |
| 4.4.3 | Strengths and limitations | 213 |
| 4.5 | Study 3: Trend of ASMR from CVD in Malaysia | 214 |
| 4.5.1 | Results | 214 |

| | | |
|----------|---|-----|
| 4.5.1(a) | Age standardized mortality rate..... | 215 |
| 4.5.1(b) | Joinpoint regression model | 218 |
| 4.5.2 | Discussion | 226 |
| 4.5.3 | Strengths and limitations | 230 |
| 4.6 | Study 4: Factors Associated with Premature CVD Mortality in Malaysia .. | 231 |
| 4.6.1 | Results | 231 |
| 4.6.1(a) | Semi-parametric survival analysis model..... | 237 |
| 4.6.1(b) | Parametric survival analysis model | 247 |
| 4.6.1(c) | Sensitivity analysis | 251 |
| 4.6.2 | Discussion | 257 |
| 4.6.3 | Limitations and strengths | 265 |
| 4.7 | Study 5: Constructing Causal Pathways for Premature CVD Mortality | 267 |
| 4.7.1 | Results stage 1 (DAG model from ESC-DAG protocol) | 267 |
| 4.7.1(a) | Mapping..... | 267 |
| 4.7.1(b) | Translation | 271 |
| 4.7.1(c) | Integration..... | 274 |
| 4.7.2 | Results stage 2 (Expert Consensus through Delphi Method)..... | 276 |
| 4.7.2(a) | First round interview..... | 276 |
| 4.7.2(b) | Second round interview | 278 |
| 4.7.2(c) | Final consensus from Fuzzy Delphi Method | 278 |
| 4.7.2(d) | Suggested adjustment set..... | 286 |
| 4.7.3 | Results stage 3 (Application of DAG model with available data)..... | 289 |
| 4.7.3(a) | Model from Expert Ranked | 293 |
| 4.7.3(b) | Model accuracy from available data..... | 295 |
| 4.7.4 | Discussion | 298 |
| 4.7.5 | Strengths and limitations | 301 |

| | |
|---|------------|
| CHAPTER 5 CONCLUSION AND RECOMMENDATIONS | 303 |
| 5.1 Overview | 303 |
| 5.2 Conclusion and recommendations for study 1 | 303 |
| 5.3 Conclusion and recommendations for study 2a | 304 |
| 5.4 Conclusion and recommendations for study 2b | 304 |
| 5.5 Conclusion and recommendations for study 3 | 305 |
| 5.6 Conclusion and recommendations for study 4 | 306 |
| 5.7 Conclusion and recommendations for study 5 | 306 |
| 5.8 Overall summary | 307 |
| 5.9 Study contributions | 308 |
| REFERENCES..... | 311 |
| APPENDICES | |
| LIST OF PUBLICATIONS | |

LIST OF TABLES

| | Page | |
|------------|---|-----|
| Table 2.1 | The International Classification of Diseases, 10th revision (ICD-10) for main CVD | 18 |
| Table 2.2 | Studies reporting non-modifiable risk factors for CVD mortality | 27 |
| Table 2.3 | Studies reporting modifiable risk factors for CVD mortality | 30 |
| Table 3.1 | Search terms for bibliometric study on premature mortality | 70 |
| Table 3.2 | Search terms for systematic review year of life lost from premature CVD mortality..... | 74 |
| Table 3.3 | Formulas for Years of Potential Life Lost (YPLL) and Standard Expected Years of Life Lost (SEYLL) | 78 |
| Table 3.4 | Data extraction form for systematic review of years of life lost from premature CVD mortality..... | 82 |
| Table 3.5 | Newcastle-Ottawa Scale for quality assessment..... | 83 |
| Table 3.6 | Search terms for systematic review of ASMR from premature CVD Mortality | 87 |
| Table 3.7 | The adapted version of Newcastle-Ottawa Scale for this study (Systematic review and Meta-analysis of ASMR for Premature CVD Mortality)..... | 93 |
| Table 3.8 | List of prognostic variables for premature CVD mortality study in Malaysia | 110 |
| Table 3.9 | Sample size calculation for survival analysis for premature CVD mortality risk profile | 114 |
| Table 3.10 | Calculation of age standardized incidence rate: Premature CVD mortality (ICD10: I00-I99) aged 30-69 years | 117 |
| Table 3.11 | Calculation of age standardized incidence rate: Premature CVD mortality (ICD10: I00-I99) aged 30-69 years among male | 118 |

| | | |
|------------|---|-----|
| Table 3.12 | Calculation of age standardized incidence rate: Premature CVD mortality (ICD10: I00-I99) aged 30-69 years among female | 119 |
| Table 3.13 | Triangular Fuzzy number from 7 Likert-scale | 132 |
| Table 4.1 | The top 10 countries contributed to the premature mortality studies according to total publication and total citation | 140 |
| Table 4.2 | The core 10 journals published the premature mortality articles with the number of publications | 142 |
| Table 4.3 | The top 10 most productive authors of premature mortality study .. | 143 |
| Table 4.4 | The frequent keywords in the premature mortality studies | 145 |
| Table 4.5 | Characteristics of selected studies; systematic review of years of life lost from cardiovascular diseases | 160 |
| Table 4.6 | Summary of total years of potential life lost (YPLL) from CVD mortality according to study characteristics | 166 |
| Table 4.7 | Summary of total standard expected years of life lost (SEYLL), from CVD mortality method from GBD study (1996) according to study characteristics | 169 |
| Table 4.8 | Characteristics of included studies; systematic review and meta-analysis of ASMR from premature CVD mortality | 183 |
| Table 4.9 | Quality assessment of 15 selected studies using an adapted version of the Newcastle-Ottawa Scale for cross-sectional studies | 185 |
| Table 4.10 | Summary of pooled ASMR per 100,000 population for premature cardiovascular mortality; Meta-analysis using random effect model | 187 |
| Table 4.11 | Sensitivity analysis of pooled ASMR per 100,000 population from premature CVD mortality by excluding the studies outlier | 202 |
| Table 4.12 | Sensitivity analysis of pooled ASMR per 100,000 population from premature CVD mortality by difference age threshold | 205 |
| Table 4.13 | Multivariable meta-regression model of log ASMR estimates from premature CVD mortality | 207 |

| | | |
|------------|--|-----|
| Table 4.14 | Population structure and age standardized mortality rate from CVD in Malaysia from 2010-2021 | 216 |
| Table 4.15 | Joinpoint regression model of age standardized mortality rate from CVD in Malaysia, 2010-2021 | 220 |
| Table 4.16 | Characteristics of Malaysia adults aged 18-69 years at baseline sampled from National Health and Morbidity Surveys (2006, 2011, 2015) and 15 years follow-up of premature cardiovascular mortality | 233 |
| Table 4.17 | Baseline characteristics and premature cardiovascular mortality in the study population for each National Health and Morbidity Survey | 235 |
| Table 4.18 | Semi-parametric Cox Proportional Hazard regression model for premature cardiovascular disease mortality in Malaysia (N = 63,722) | 239 |
| Table 4.19 | Hazard ratio of premature cardiovascular disease mortality for the interaction Cox models | 246 |
| Table 4.20 | Parametric survival analysis models of premature cardiovascular disease mortality in Malaysia..... | 249 |
| Table 4.21 | Sensitivity analysis treated of imbalance data for unadjusted survival analysis model of premature cardiovascular disease mortality in Malaysia | 254 |
| Table 4.22 | Sensitivity analysis comparing treated imbalance data to original data for the adjusted premature cardiovascular disease mortality survival analysis model | 256 |
| Table 4.23 | Summary of Fuzzy Delphi Method findings..... | 279 |
| Table 4.24 | Suggested adjustment set for total effect of selected exposure toward premature CVD mortality | 287 |
| Table 4.25 | DAG models for expert domain rate and testing model accuracy with available data..... | 290 |
| Table 4.26 | Expert ranked the proposed DAG model | 294 |

| | |
|--|-----|
| Table 4.27 Comparison model accuracy from data based on Logistic Regression models | 297 |
|--|-----|

LIST OF FIGURES

| | Page | |
|------------|--|-----|
| Figure 2.1 | World Health Organization (WHO) framework of social determinants of health, 2010..... | 36 |
| Figure 2.2 | Type of bibliometric analysis..... | 40 |
| Figure 2.3 | Steps for systematic review study | 44 |
| Figure 2.4 | Survival and Hazard Functions for selected distribution | 54 |
| Figure 2.5 | Model classification in survival analysis | 55 |
| Figure 2.6 | Terminology in directed acyclic graphs (DAGs) | 60 |
| Figure 2.7 | Key concept of causal path in directed acyclic graphs (DAGs)..... | 62 |
| Figure 2.8 | Framework of Causal Inference | 64 |
| Figure 3.1 | Summary of methods for the overall study | 68 |
| Figure 3.2 | Flow chart of the data cleaning process | 115 |
| Figure 3.3 | Flow chart of study constructing DAG model for premature cardiovascular mortality..... | 127 |
| Figure 3.4 | Summary of evidence synthesis for constructing DAG (ESC-DAG) protocol | 129 |
| Figure 4.1 | Flow diagram of study selection process | 138 |
| Figure 4.2 | Number of articles related to premature mortality | 139 |
| Figure 4.3 | Collaboration of countries publishing articles related to premature mortality..... | 141 |
| Figure 4.4 | The top author's production over time..... | 144 |
| Figure 4.5 | Trending keywords related to premature mortality between 2002 and 2021 | 146 |
| Figure 4.6 | Thematic map of publications related to premature mortality | 148 |
| Figure 4.7 | Co-occurrence keywords related to premature mortality..... | 150 |

| | | |
|-------------|---|-----|
| Figure 4.8 | Flow diagram of the published articles evaluated for inclusion in this review | 157 |
| Figure 4.9 | Distribution of selected studies by country | 158 |
| Figure 4.10 | The YPLL rate of countries with available data | 168 |
| Figure 4.11 | The SEYLL rate of countries with available data..... | 171 |
| Figure 4.12 | Patterns of YPLL rate (a) and SEYLL rate (b) according to CVD types and WHO regions | 173 |
| Figure 4.13 | Patterns of YPLL rate (a) and SEYLL rate (b) according to sex and WHO regions | 174 |
| Figure 4.14 | Patterns of SEYLL rate by WHO regions..... | 175 |
| Figure 4.15 | Flow diagram of the published articles evaluated for inclusion in this review | 182 |
| Figure 4.16 | Forest plot of ASMR per 100,000 population from premature CVD mortality (all studies) with subgroup analysis by CVD types | 188 |
| Figure 4.17 | Forest plot of ASMR per 100,000 population from premature CVD mortality (all studies) with subgroup analysis by sex (excluded both sex)..... | 190 |
| Figure 4.18 | Forest plot sex-specific premature mortality (ASMR per 100,000 population) from all CVD (ICD-10 codes I00-I99 or ICD-9 codes 350-459) | 191 |
| Figure 4.19 | Forest plot sex-specific premature mortality (ASMR per 100,000 population) from IHD (ICD-10 codes I20-I25 or ICD-9 codes 410-414) | 192 |
| Figure 4.20 | Forest plot sex-specific premature mortality (ASMR per 100,000 population) from cerebrovascular disease or stroke (ICD-10 codes I60-I69 or ICD-9 codes 430-438) | 193 |
| Figure 4.21 | Forest plot of ASMR per 100,000 population from premature CVD mortality (all studies) with subgroup analysis by income country level..... | 195 |

| | | |
|-------------|---|-----|
| Figure 4.22 | Forest plot of ASMR per 100,000 population from premature mortality among total CVD (ICD-10 codes I00-I99 or ICD-9 codes 350-459) with subgroup analysis by income country classification | 196 |
| Figure 4.23 | Forest plot of ASMR per 100,000 population from premature CVD mortality (all studies) with subgroup analysis by study time..... | 198 |
| Figure 4.24 | Forest plot time-stratified analysis of premature CVD mortality (ASMR per 100,000 population) among high income countries | 199 |
| Figure 4.25 | Forest plot time-stratified analysis of premature CVD mortality (ASMR per 100,000 population) among middle (low and upper) income countries | 200 |
| Figure 4.26 | Funnel plot to assess publication bias of overall studies (a) and total CVD (b)..... | 208 |
| Figure 4.27 | The ASMR trend from CVD in Malaysia from 2010 to 2021; (A) Overall population by age group; (B) Male by age group and (C) Female by age group | 217 |
| Figure 4.28 | Joinpoint regression model of age standardized mortality rate (ASMR) per 100,000 from CVD in Malaysia, 2010-2021 for overall CVD (a) and by sex (b) | 222 |
| Figure 4.29 | Joinpoint regression model of age standardized mortality rate (ASMR) per 100,000 from CVD in Malaysia, 2010-2021by age group in male (a) and female (b)..... | 224 |
| Figure 4.30 | Schoenfeld residual test and plot for each covariate before stratified Cox model..... | 241 |
| Figure 4.31 | Schoenfeld residual test and plot for each covariate after stratified Cox model by age of entry | 243 |
| Figure 4.32 | Parametric distribution fits to premature CVD mortality data by estimating baseline parametric models (without covariates) | 248 |
| Figure 4.33 | Parametric distribution fittings for premature CVD mortality data after treatment using under-sampling method on imbalanced data . | 253 |

| | | |
|-------------|---|-----|
| Figure 4.34 | Framework-related variables for premature cardiovascular mortality | 269 |
| Figure 4.35 | ESC-DAG process (Mapping) - Implied graph (IG) for premature CVD from mapping stage | 270 |
| Figure 4.36 | ESC-DAG process (Translation) - Translation of Implied graph to DAG for Premature CVD Mortality | 273 |
| Figure 4.37 | ESC-DAG process (Integration) - The final I-DAG for premature cardiovascular mortality | 275 |
| Figure 4.38 | DAG for premature CVD mortality from first round interview by expert domains | 277 |
| Figure 4.39 | Final DAG for premature CVD mortality from evidence synthesis and expert consensus..... | 285 |

LIST OF SYMBOLS

| | |
|---------|------------------------|
| % | Percentage |
| p | P value |
| = | Equal to |
| > | More than |
| < | Less than |
| \geq | More than and equal to |
| \leq | Less than and equal to |
| e | Exponential |
| β | Beta |

LIST OF ABBREVIATIONS

| | |
|--------------|---|
| AANS | American Association of Neurological Surgeons |
| AAPC | Average annual percentage change |
| ACLS | Aerobics Center Longitudinal Study |
| ACS | Acute coronary syndromes |
| AFT | Accelerated failure time |
| AIC | Akaike Information Criterion |
| AO | Abdominal obesity |
| APC | Annual percentage change |
| ASIR | Age-standardized incidence rate |
| ASMR | Age-standardized mortality rate |
| ASSIGN-SCORE | Assign Preventative Treatment - Systematic Coronary Risk Evaluation |
| ASYR | Age-standardized Years of Life Lost rates |
| AUC | Area under curve |
| BIC | Bayes Information Criterion |
| BMI | Body Mass Index |
| CDC | Centers for Disease Control |
| CENTRAL | Cochrane Central Register of Controlled Trials |
| CHD | Coronary heart disease |
| CI | Confidence intervals |
| COVID-19 | Coronavirus disease 2019 |
| CPI | Consumer Price Indices |
| CVA | Cerebral vascular accident |
| CVD | Cardiovascular disease |
| DAG | Directed Acyclic Graph |
| DALYs | Disability-adjusted life-years |
| DM | Diabetes mellitus |
| DOSM | Department of Statistics Malaysia |
| EPIC | European Prospective Investigation into Cancer and Nutrition |
| ESC-DAG | Evidence Synthesis for Constructing Directed Acyclic Graphs |
| ETR | Event Time Ratio |
| FDM | Fuzzy Delphi method |
| FRS | Framingham risk score |
| GBD | Global Burden of Disease |
| GO | General obesity |
| GPAQ | Global Physical Activity Questionnaire |
| HDL | High-density lipoprotein |
| HICs | High-income countries |
| HPL | Hyperlipidemia |
| HPT | Hypertension |
| HR | Hazard Ratio |

| | |
|----------|---|
| ICD-10 | International Statistical Classification of Diseases, 10th revision |
| I-DAG | Integrated Directed Acyclic Graph |
| IDE | Integrated Development Environment |
| IG | implant graph |
| IHD | Ischemic heart disease |
| IHME | Institute for Health Metrics and Evaluation |
| IPAQ | International Physical Activity Questionnaire |
| IQR | Interquartile range |
| JEPeM | Jawatankuasa Etika Penyelidikan (Manusia) |
| LICs | Low-income countries |
| LMICs | Low-middle-income countries |
| MET | Metabolic equivalent of task |
| MICs | Middle-income countries |
| MRFTT | Multiple Risk Factor Intervention Trial |
| NCD | Non-communicable disease |
| NCHS | National Center for Health Statistics |
| NHANES | National Health and Nutrition Examination Survey |
| NHMS | National Health and Morbidity Survey |
| NMRR | National Medical Research Register |
| NOS | Newcastle-Ottawa Scale |
| NRD | National Registration Department |
| NRIC | National Registration Identity Card |
| NSTEMI | Non-ST elevation (NSTEMI) myocardial infarction |
| OR | Odd Ratio |
| PAHO | Pan American Health Organization |
| PH | Proportional hazards |
| PHS | Physicians' Health Study |
| PI | Prediction interval |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PROCAM | Prospective Cardiovascular Münster |
| PROSPERO | International Prospective Register of Systematic Reviews |
| PSC | Prospective Studies Collaboration |
| PURE | Prospective Urban Rural Epidemiology |
| QRISK | QRESEARCH cardiovascular risk |
| QUORUM | Quality of Reporting of Meta-Analyses |
| ROC | Receiver operating curve |
| SAS | Statistical Analysis Software |
| SCORE | Systematic Coronary Risk Evaluation |
| SCS | Seven Countries Study |
| SDG | Sustainable Development Goals |
| SDH | Social determinants of health |
| SE | Standard error |
| SES | Socioeconomic status |
| SEYLL | Standard Expected Years of Life Lost |

| | |
|---------|---|
| SMR | Standardized mortality ratio |
| SPSS® | Statistical Package for the Social Sciences |
| STEMI | ST elevation myocardial infarction |
| TCS | Thai Cohort Study |
| TFN | Triangular Fuzzy Number |
| UK | United Kingdom |
| USA | United State of America |
| WC | Waist circumference |
| WHO | Word Health Organization |
| WHO/ISH | World Health Organisation-International Society of Hypertension |
| WoS | Web of Science |
| YLL | Years of Life Lost |
| YPLL | Years of Potential Life Lost |

LIST OF APPENDICES

| | |
|------------|---|
| Appendix A | PRISMA checklist (Study Phase 2) |
| Appendix B | Approval for the usage of mortality data from the Department of Statistics Malaysia (Study Phase 3) |
| Appendix C | Approval letter for the NHMS data from the Unit of Biostatistics & Data Repository, NIH (Study Phase 4) |
| Appendix D | Expert invitation letter for constructing a causal model for premature CVD mortality (Study Phase 5) |
| Appendix E | Questionnaire for Consensus-Building with Experts for Constructing a DAG Causal Pathway for Premature CVD Mortality (Study Phase 5) |
| Appendix F | Ethical approval from Medical Research & Ethics Committee, Ministry of Health Malaysia |
| Appendix G | Ethical approval from Jawatankuasa Etika Penyelidikan Manusia (JEPeM), USM |
| Appendix H | R code for statistical analysis |
| Appendix I | Excel worksheet template for calculating fuzzy Delphi method |

KEMATIAN PRAMATANG DARIPADA PENYAKIT
KARDIOVASKULAR: BEBAN GLOBAL DAN ANGGARAN KHUSUS
NEGARA MELALUI KAJIAN SEMAKAN, ANALISIS TREND,
PEMODELAN RAMALAN, DAN PENYEBAB KAJIAN INFERENS

ABSTRAK

Penyakit kardiovaskular merupakan penyebab utama kematian pramatang di seluruh dunia, dengan beban penyakitnya kian meningkat dalam beberapa tahun terkini. Walaupun banyak penyelidikan telah dilakukan berkaitan dengan penyakit kardiovaskular, namun, terdapat jurang dalam mengenalpasti perkaitan kematian pramatang dengan kardiovaskular. Sebagai contoh, terdapat maklumat yang tidak mencukupi mengenai aktiviti penyelidikan global dan anggaran kumpulan beban kematian pramatang akibat penyakit kardiovaskular dari sumber kajian yang sedia ada. Selain itu, anggaran beban ini dalam negara dan profil risiko penyakit kardiovaskular yang khusus untuk setiap negara turut kurang. Justeru itu, tesis ini bertujuan untuk menganalisis dan memahami secara menyeluruh pelbagai aspek kematian pramatang berkaitan penyakit kardiovaskular, termasuk aktiviti penyelidikan secara global, membuat anggaran global beban kematian pramatang disebabkan penyakit kardiovaskular, mengenalpasti trend dan profil risiko bagi kematian pramatang penyakit kardiovaskular secara spesifik di dalam negara, serta membina model laluan kausa bagi kematian pramatang penyakit kardiovaskular. Tesis ini terdiri daripada lima kajian yang berkaitan bertujuan untuk menjawab semua objektif penyelidikan. Kajian pertama meringkaskan maklumat penerbitan global yang berkaitan dengan kematian pramatang melalui analisis bibliometrik. Analisis bibliometrik menunjukkan bahawa penyelidikan kematian pramatang telah meningkat secara ketara dalam sedekad yang

lalu; namun, terdapat perbezaan dalam hasil penyelidikan antara negara berpendapatan tinggi (HICs) dan negara berpendapatan rendah dan pertengahan (LMICs). Kajian ini menekankan keperluan untuk usaha kerjasama di negara LMICs. Dalam kajian kedua, terdiri daripada dua bahagian: kajian 2a merupakan kajian ulasan sistematik yang menumpukan kepada kematian pramatang penyakit kardiovaskular menggunakan indikator jumlah tahun hayat (YLL), diikuti oleh kajian 2b, meta-analisis berdasarkan indikator kadar kematian diselaras mengikut umur (ASMR). Hasil kajian 2a dan 2b ini menunjukkan beban yang berterusan kematian pramatang penyakit kardiovaskular, terutamanya di negara LMICs dan di kalangan lelaki. Kajian ketiga melibatkan analisis trend menggunakan data kematian spesifik negara dari Jabatan Perangkaan Malaysia dan menggunakan kaedah model regresi joinpoint. Kajian ini mendapati peningkatan kadar kematian pramatang penyakit kardiovaskular di Malaysia secara berterusan dalam satu dekad yang lalu, menunjukkan beban yang berterusan di negara ini. Dalam kajian keempat, satu kajian pemodelan dijalankan untuk menilai profil risiko kematian pramatang penyakit kardiovaskular dengan menggunakan pelbagai model survival. Kajian ini menggunakan data daripada Tinjauan Kebangsaan Kesihatan dan Morbiditi (NHMS), Malaysia yang dijalankan pada tahun 2006, 2011, dan 2015, dan dipadankan dengan rekod kematian sehingga tahun 2021. Model survival semi-parametrik dan parametrik kedua-duanya menunjukkan status sosioekonomi dan faktor risiko yang boleh diubah merupakan faktor risiko penting terhadap kematian pramatang penyakit kardiovaskular di Malaysia. Kajian ini menekankan keperluan untuk intervensi berpusat bagi mengurangkan kesan ini secara berkesan. Akhirnya, kajian kelima melibatkan satu kajian kesimpulan kausa dimana fasa ini menunjukkan proses secara sistematik untuk membina model Directed Acyclic Graph (DAG) bagi kematian pramatang penyakit kardiovaskular. Kajian ini memperkenalkan pendekatan baru yang

mengintegrasikan bukti sintesis dan pendapat pakar menggunakan kaedah Fuzzy Delphi untuk membina model DAG, diikuti dengan menguji model dengan data yang ada. Proses langkah demi langkah yang ditunjukkan untuk membina model kausa ini, menawarkan pendekatan sistematik, praktikal, transparan, dan menyumbang kepada metodologi DAG. Secara keseluruhan, melalui metodologi yang teliti, dapatan tesis ini menyumbang kepada perkembangan karya sastera tentang kematian pramatang dari penyakit kardiovaskular dan memberikan input dan kerangka nilai yang berharga untuk memberi informasi kepada strategi kesihatan awam dan membimbing usaha penyelidikan masa depan dalam menangani kematian pramatang penyakit kardiovaskular.

**PREMATURE MORTALITY FROM CARDIOVASCULAR DISEASE:
GLOBAL BURDEN AND COUNTRY-SPECIFIC ESTIMATE THROUGH
REVIEW STUDY, TREND ANALYSIS, PREDICTION MODELLING, AND
CAUSAL INFERENCE STUDY**

ABSTRACT

Cardiovascular disease (CVD) is a leading cause of premature mortality worldwide, with its burden growing in recent years. Despite considerable research into CVD, there are noticeable gaps in addressing premature mortality associated with it. For example, there is insufficient information on global research activity and pool estimation of the global burden of premature CVD mortality from existing literature. Additionally, within-country estimates of this burden and country-specific CVD risk profiles are lacking. Therefore, this thesis aims to comprehensively analyze and understand various aspects of premature CVD mortality, including global research activities, estimating the global burden of CVD related to premature mortality, examining country-specific trends and risk profiles for premature CVD mortality, and constructing causal pathways for premature CVD mortality. This thesis consists of five interrelated studies aimed at addressing all research objectives. The first study summarizes the global publication information related to premature mortality through bibliometric analysis. The bibliometric analysis shows that premature mortality research has increased substantially in the past decade; however, there have been disparities in research output between high-income countries (HICs) and low-middle-income countries (LMICs), emphasizing the need for collaborative efforts in LMICs. In the second study, consisting of two parts: Study 2a, a systematic review concentrating on premature CVD mortality using the Years of Life Lost (YLL)

indicator, followed by study 2b, a subsequent meta-analysis based on the age-standardized mortality rate (ASMR) indicator. Studies 2a and 2b underscore the persistent burden of premature CVD mortality, particularly in LMICs and among men, emphasizing the importance of targeted interventions and public health strategies. The third study involves trend analysis utilizing Malaysia country-specific mortality data from Department of Statistics Malaysia employing a joinpoint regression model. This study reveals a persistent increasing trend of premature CVD mortality rates in Malaysia over the past decades, underscoring the ongoing burden in the country. In study four, a modeling study is conducted to assess the premature CVD risk profile by applying various survival models. This study utilizes data from Malaysia's National Health and Morbidity Survey (NHMS) conducted in 2006, 2011, and 2015, linked with mortality records through 2021. The semi-parametric and parametric survival models both highlight the considerable impact of socioeconomic status and modifiable risk factors on premature CVD mortality in Malaysia. Finally, the fifth study entails a causal inference study systematically demonstrating the construction of a Directed Acyclic Graph (DAG) model for premature CVD mortality. This study introduces a new approach integrating evidence synthesis and expert opinion using the Fuzzy Delphi method to construct the DAG model, followed by testing the model with available data. This step demonstrates a step-by-step process for constructing a causal model, offering a systematic, practical, and transparent approach, contributing to DAG methodology. In summary, through meticulous methodologies, the findings of this thesis contribute to the growing body of literature on premature mortality from CVD and provide valuable insights and frameworks for informing public health strategies and guiding future research endeavours in tackling premature CVD mortality.

CHAPTER 1

INTRODUCTION

1.1 Background of the study

Cardiovascular diseases (CVDs) encompass a wide range of disorders, from conditions affecting the heart muscle to those impacting the blood vessels supplying the heart, brain, and other vital organs (Gaziano *et al.*, 2006). Globally, CVD continues to be the leading cause of morbidity and mortality, imposing significant social and economic burdens. In 2017, an estimated 17.8 million people died from CVDs worldwide, resulting in the loss of 330 million years of life and an additional 35.6 million years lived with disability (Kyu *et al.*, 2018; Roth *et al.*, 2018a). Notably, approximately 80% of CVD deaths occur in low- and middle-income countries (LMICs) (WHO, 2021a).

In addition to the staggering number of deaths caused by CVDs, a significant portion comprises premature mortality. Premature mortality is defined as a death that occurs before the average age of death in a particular population (National Cancer Institute, 2021a). It is a measure of unfulfilled life expectancy. The trends in premature mortality globally from 1990–2017 have shown a 41% decrease in communicable diseases and neonatal disorders but a 40% increase in non-communicable diseases (NCDs) (IHME., 2017).

According to the Global Burden of Disease (GBD) study, CVDs, the main types of NCDs, continue to dominate as the leading causes of premature mortality worldwide (Roth, Huffman, *et al.*, 2015a). Principally, ischemic heart disease (IHD) and cerebrovascular disease account for approximately one-third of all global premature deaths (Roth, Huffman, *et al.*, 2015b; Vos *et al.*, 2020). Together with

cancer, respiratory diseases, and diabetes, they collectively contribute to over 80% of all premature mortality due to NCDs (WHO, 2022). LMICs bear a disproportionately high burden of premature mortality compared to high-income countries (HICs) (WHO, 2022). Furthermore, CVDs in LMICs are significant contributors to the escalating burden of NCDs, accounting for approximately 86% of all premature NCD deaths globally (WHO, 2022).

Similarly, in Malaysia, CVD has been the leading cause of death since the 1990s and remains a significant threat, contributing to around 35% of premature mortality in the country (WHO, 2018a; Noor, Muzafar & Khalidi, 2020). In 2018, IHD continued as the predominant cause of premature mortality among Malaysians, while stroke was positioned as the fourth ranking (Khaw *et al.*, 2023).

Premature CVD mortality is influenced by various risk factors, categorized as non-modifiable and modifiable. Non-modifiable factors like age, sex, and ethnicity are beyond our control but affect CVD susceptibility (Choudhury *et al.*, 2015; Lotufo, 2015; Mohammadnezhad *et al.*, 2016; J. Zhang, Jin, Jia, Li & Z.-J. Zheng, 2021). On the other hand, modifiable risk factors allow targeted interventions and lifestyle changes to reduce CVD morbidity and mortality.

Among the key modifiable risk factors, metabolic factors such as diabetes, hypertension, hyperlipidemia, and obesity significantly contribute to premature CVD mortality (Eslami *et al.*, 2019; Yusuf *et al.*, 2020; Joseph *et al.*, 2022). Furthermore, beyond metabolic factors, various behavioral risk factors significantly escalate the incidence of premature CVD mortality. These include smoking (Eslami *et al.*, 2019; Joseph *et al.*, 2022), excessive alcohol consumption (Leon *et al.*, 2007), physical inactivity, and sedentary lifestyles, all of which play critical roles in elevating CVD

mortality rates (WHO, 2021c). Effective management and early detection of individuals with CVD and its risk factors, particularly behavioral and modifiable ones, necessitate targeted interventions to mitigate premature mortality.

1.2 Problem statement

Although extensive research has been conducted on CVD from various angles, there remains a need for more studies focusing on CVD-related premature mortality both globally and within specific countries. From a global perspective, there is insufficient research on the overall global research activity concerning premature mortality and the estimation of the global burden specifically attributable to CVD-related premature deaths based on existing literature.

Firstly, while the academic literature on premature mortality has expanded recently, there is a lack of comprehensive information regarding the total number and distribution of published articles in this area. Bibliometric analysis, a valuable method for exploring the distribution of publications, evaluating research progress, uncovering emerging research trends, and identifying relevant topics related to any field of study, could provide valuable insights into the current state of research activity. Extracting knowledge from existing studies is crucial for identifying current developments and future trends, which is essential for assessing the relevance of topics related to premature mortality.

Secondly, despite the extensive investigation of CVD mortality through systematic reviews and meta-analyses, premature mortality has frequently been overlooked as an outcome measure. These analyses typically focus on establishing predictors of increased mortality, relative risks, or risk factors for cause-specific mortality (Aviña-Zubieta *et al.*, 2008; Nocon *et al.*, 2008; Huang *et al.*, 2014; Qiu *et*

al., 2021) rather than emphasizing premature death age-related to CVD. Meanwhile, the GBD study, the most widely used global estimate of premature mortality, has derived estimates of global premature CVD mortality with missing or limited-quality mortality data in some countries, particularly in the poorest regions (Roth *et al.*, 2018b; Stanaway *et al.*, 2018). To the best of researcher knowledge, there has yet to be a comprehensive systematic review and meta-analysis that synthesizes the available evidence on premature CVD mortality, specifically focusing on estimating a pooled effect size using metrics such as years of life lost (YLL) and age-standardized mortality rate (ASMR), common methods for measuring the burden of premature mortality. Incorporating diverse parameters in such an analysis would offer a thorough evaluation of premature CVD mortality, thus contributing significantly to the development of global strategies aimed at addressing this critical public health concern.

Turning to a country-specific perspective, investigating trends in CVD mortality within countries, especially in LMICs like Malaysia, is crucial. However, Malaysia's CVD mortality trends have remained unexplored over the past decade. Analyzing Malaysia's data from vital statistics would provide valuable insights for policy and intervention strategies. While joinpoint analysis is a statistical method commonly used to detect changes in trends or patterns in data over time, including the impact of CVD mortality rates, it has not been applied to examine the trend and any change in the mortality rate from CVD in Malaysia over the past decade.

Furthermore, the risk factors for premature CVD mortality vary across regions and income levels. The PURE project, studying 155,722 participants across 21 countries, found differing impacts based on income levels (Yusuf *et al.*, 2020). In

middle-income countries (MICs), hypertension, metabolic, and behavioral factors are significant, with low education having a pronounced effect compared to HICs. In low-income countries (LICs), metabolic factors, household air pollution, and poor diet are key risks (Yusuf *et al.*, 2020). In South Asia, a cohort study of 33,583 individuals highlighted the impact of low education, weak physical strength, and poor diet quality (Joseph *et al.*, 2022). Similarly, in China, hypertension remains a primary risk factor, with low education ranking high for both CVD and mortality (Li *et al.*, 2022). Such diversity in risk profiles likely contributes to variations in CVD mortality rates across the Asian region. Malaysia's diverse population encompasses various ethnicities, each with distinct genetic predispositions and lifestyle habits that can influence CVD risk profiles. Despite existing research on CVD risk factors, the study of premature CVD mortality in Malaysia remains limited, especially in employing survival analysis to model modifiable risk factors associated with premature CVD mortality using population-based data. Such information is crucial for informing policy formulation and public health strategies for controlling and preventing CVDs in Malaysia.

Lastly, while numerous models predict CVD mortalities (Lynch *et al.*, 1996; Eslami *et al.*, 2017; Joseph *et al.*, 2022), most risk prediction and causation models in epidemiology rely on additive combinations of risk factors within a regression model framework. However, these models may not accurately represent the causal pathways underlying disease development. It's crucial in epidemiological studies to distinguish between prediction and causal approaches to ensure valid interpretation of the evidence.

Causal inference approaches explicitly consider causality and describe the influence of variables on disease outcomes by accounting for causal pathways between

them (Pearl, 2009). Directed Acyclic Graphs (DAGs) serve as a valuable tool to represent causal models (Pearl & others, 2000; Pearl, Glymour & Jewell, 2016). A DAG shows causal links between variables using arrows connecting nodes. Theory and background knowledge are central to DAG construction, and drawing a DAG before analysis is crucial for guiding the selection of confounding variables in a study (Robins & Wasserman, 1999; Robins, 2001; Hernán *et al.*, 2002; Sauer *et al.*, 2013).

Despite the importance of DAGs, there is currently no systematic documentation of standard methods or protocols for constructing them, particularly in epidemiological studies. Although Ferguson *et al.* (2020) introduced a systematic approach called Evidence Synthesis for Constructing Directed Acyclic Graphs (ESC-DAG), there remains a need for practical guidance on drawing DAGs, incorporating the experience and knowledge of domain experts (Ferguson *et al.*, 2020). Therefore, a comprehensive methodology that integrates evidence synthesis and expert domains is necessary to provide practical guidance on drawing DAGs and applying them effectively in data analysis. Researchers can use this approach as an additional tool for selecting adjustment variables when analyzing epidemiological data.

Therefore, this thesis aims to address existing gaps in the literature through meticulous methodological analyses and study design to estimate the global and country-specific burdens, as well as the risk factors, for premature CVD mortality. From a global perspective, this study adopts a comprehensive approach, utilizing bibliometric analysis, systematic review, and meta-analysis to investigate global research activity on premature mortality and estimate the global burden of CVD-related premature mortality. For the country-specific perspective, Malaysia's vital registration data is used in a modeling study employing a joinpoint regression model

to analyze trends in CVD mortality rates in Malaysia. To estimate specific risk factors and construct a causal model, survival analysis—incorporating both semi-parametric and parametric survival models—is applied to assess the CVD risk profile using population-based surveys from Malaysia linked with mortality data. Finally, this thesis employs causal inference methodology, demonstrating a systematic process for constructing a DAG as a causal model for premature CVD mortality. This integrates both evidence synthesis and expert consensus to provide a robust framework for understanding causal pathways.

1.3 Research questions

The primary research question for this study is: What are the global estimates of premature CVD mortality, and what are the country-specific trends, risk factors, and causal pathways? This overarching question is explored through the following specific research questions:

- I. What are the characteristics of publications on premature mortality, particularly concerning the distribution of publications, citations, countries involved, collaboration patterns, author productivity, trending keywords, and relevant research topics?
- II. What are the characteristics and findings of studies investigating premature CVD mortality, explicitly focusing on years of life lost?
- III. What is the pooled estimate of age-standardized mortality rates for premature CVD mortality derived from a systematic review and meta-analysis of relevant studies?
- IV. What are the temporal trends in age-standardized mortality rates related to CVD in Malaysia between 2010 and 2021?

- V. What prognostic factors are associated with premature CVD mortality in Malaysia, specifically focusing on modifiable risk factors?
- VI. What causal pathways underlie premature CVD mortality, and how can they be constructed through a comprehensive approach integrating evidence synthesis and expert domain knowledge utilizing the DAGs method?

1.4 Research objectives

1.4.1 General objective

The general objective of this study is to determine the patterns and burdens of premature mortality from CVD, as well as its contributing factors and causal pathways.

1.4.2 Specific objectives

- I. To explore the characteristics of the publications on premature mortality from all causes of death, in terms of the number of publications, citations, countries, collaboration, and author's productivity and further identify the trending keyword and relevant research topic.
- II. To identify the studies on premature CVD mortality and synthesise their findings on years of life lost based on the regional area, main CVD types, sex, and study time.
- III. To estimate the pooled age-standardized mortality rates of premature CVD mortality through a comprehensive systematic review with meta-analysis, providing both global estimates and pooled estimates by sex, major types of CVD, income, country level, and study period.
- IV. To explore the trend and changes in CVD mortality rates in Malaysia using age-standardized mortality rates from 2010 to 2021 among all age groups, including premature mortality, using Malaysia's vital registration data.

- V. To determine the prognostic factors associated with premature CVD mortality in Malaysia, with a particular focus on modifiable risk factors among Malaysian adults aged below 70 years who died from CVD, using Malaysia's population-based data linked with death records.
- VI. To construct causal pathways for premature CVD mortality based on a comprehensive approach integrating evidence synthesis and expert domain knowledge through DAGs.

1.5 Overview of studies

The PhD project comprises of five interrelated studies aimed at addressing all research objectives. The first study focused on conducting a bibliometric analysis of premature mortality to enhance understanding of global research activities on premature mortality across all causes of death. In the second study, a systematic review was conducted specifically on premature mortality due to CVD, consisting of two parts: a systematic review concentrating on premature CVD mortality using the YLL indicator, followed by a subsequent meta-analysis based on the ASMR indicator.

The third study involved trend analysis utilizing country-specific mortality data from vital registration employing a joinpoint regression model. In the fourth study, a modeling analysis was conducted to assess the premature CVD risk profile by applying various survival models. Finally, the fifth study entailed a causal inference study systematically demonstrating the construction of a DAG model for premature CVD mortality. An overview of each study, including methods and main findings, is provided below.

1.5.1 Study 1: Bibliometric analysis on premature CVD mortality

This study aimed to explore the characteristics of publications on premature mortality, including publication numbers, citations, countries involved, collaboration patterns, author productivity, and identifying trending keywords and relevant research topics. Articles related to premature mortality data were retrieved from the Web of Science (WoS) database using specific search terms. A Bibliometrix package from R software was used to perform bibliometric analyses. A total of 1,060 original research articles and reviews were analyzed, revealing a significant increase in publications over the past decade, with the United States of America (USA) leading in research output and collaboration. Thematic mapping highlighted CVD as the primary research domain, with potential areas for future research including air pollution and neurodegeneration. These findings provide valuable insights for scholars, potential collaborators, and future research endeavors in understanding and addressing premature mortality globally.

1.5.2 Study 2a: Systematic review on years of life lost from CVD mortality

The objective of this study was to identify studies on premature CVD mortality and synthesize their findings using the YLL indicator, focusing on regional areas, major CVD types, sex, and study period. A systematic review was conducted across multiple databases including PubMed, Scopus, WoS, and the Cochrane Central Register of Controlled Trials (CENTRAL), yielding 40 eligible studies. These studies, representing various WHO regions, reported both Years of Potential Life Lost (YPLL) and Standard Expected Years of Life Lost (SEYLL), methods that are commonly used to calculate YLL. Results showed varying rates across income countries, with middle income countries (MICs) experiencing higher rates. Over three decades, there was a slight increase in YPLL and SEYLL rates for overall CVD and IHD, while

cerebrovascular disease rates slightly decreased. Males exhibited higher rates compared to females, particularly in the increase over time. The study concludes that premature CVD mortality remains a significant burden for MICs, necessitating urgent strategies to mitigate this mortality gap.

1.5.3 Study 2b: Meta analysis of ASMR from premature CVD Mortality

In this study, the pooled ASMR of premature CVD mortality was estimate. Through a systematic review of articles published up to October 2022 in PubMed, Scopus, WoS, and CENTRAL databases, 15 studies meeting the inclusion criteria were identified. The pooled estimate of ASMR was calculated using random-effects meta-analysis in R software. The global ASMR for premature CVD mortality was estimated at 96.04 per 100,000 people, with subgroup analyses revealing higher rates for IHD compared to cerebrovascular disease or stroke. Sex-specific differences showed higher ASMRs for males than females, while MICs exhibited significantly higher ASMRs compared to HICs. Stratifying by age group indicated that the age groups of 20–64 years and 30-74 years had a higher ASMR than the age group of 0-74 years. The multivariable meta-regression model suggested significant differences in the adjusted ASMR estimates for all covariates except study time. The findings underscore the persistent burden of premature CVD mortality, particularly in MICs, emphasizing the need for targeted interventions in these populations.

1.5.4 Study 3: Trend of ASMR from CVD in Malaysia

This study aimed to investigate trends and changes in CVD mortality rates in Malaysia from 2010 to 2021. Data on the Malaysian population and mortality were obtained from the Department of Statistics Malaysia (DOSM). ASMRs for CVD per 100,000 population were calculated using the World Health Organization (2000-2025) standard population using the direct method. ASMRs were stratified by sex, age groups

(including premature mortality ages 30-69 years), and CVD types. The annual percent change (APC) and average annual percent change (AAPC) of ASMRs were estimated using an advanced regression modelling known as the joinpoint regression model. Results indicated a notable increase in all age CVD ASMRs from 93.1 to 147.0 per 100,000 population during the study period, with an AAPC of 3.6%. The increase was particularly prominent between 2015 and 2018. The study highlights the persistent burden of premature CVD mortality (age 30-69) in Malaysia, particularly among males, underscoring the ongoing challenge of premature CVD mortality in the country.

1.5.5 Study 4: Prognostic Factors for Premature CVD Mortality in Malaysia

This study employs advanced semi and full parametric survival analysis to model modifiable risk factors among Malaysian adults. Utilizing data from Malaysia's National Health and Morbidity Survey (NHMS) conducted between 2006 and 2015, linked with mortality records, the study analyzes a cohort of 63,722 individuals aged 18 to 69. Among them, 1.4% experienced premature CVD mortality, with an age-standardized incidence rate (ASIR) of 1.80 per 1000 person-years. Employing six survival models, including a semi-parametric Cox proportional hazard model and five parametric survival models (Exponential, Weibull, Gompertz, log-normal and log-logistic), the study found that the best-fit survival models were the stratified Cox model by age and the log-normal accelerated failure time model. Males, rural residents, and those with lower education levels faced higher risks, while diabetes, hypertension, hypercholesterolemia, smoking, and abdominal obesity were associated with increased mortality risk and reduced survival time. These findings underscore the significant impact of socioeconomic status and modifiable risk factors on premature CVD mortality, highlighting the need for targeted interventions.

1.5.6 Study 5: Constructing DAG model for Premature CVD Mortality

This study presents a novel methodology for constructing a causal model for premature CVD mortality, integrating evidence synthesis and expert consensus across three stages. In Stage 1, the research team develops a draft DAG model based on the ESC-DAG framework. Subsequently, in Stage 2, the model undergoes validation and consensus-building with 12 experts through two rounds of interviews, using the Fuzzy Delphi method (FDM) for final consensus. In this phase, the initial draft DAG model was revised based on expert consensus, and the suggested minimal adjustment set from this final DAG model guided the selection of confounding variables for adjustment as a general reference for epidemiological studies on premature CVD mortality. For example, to estimate the total effect of diabetes on premature CVD mortality, the suggested minimal adjustment set included age, dietary pattern, genetic or family history, sex hormones, and physical activity. In the final stage, the model is applied to guide data analysis, proposing three feasible DAG models using population-based survey data linked with death records. Testing different DAG models in this stage revealed consistent agreement between expert ratings and data accuracy from regression models for the suggested adjustment set. The study concludes that integrating evidence synthesis with expert opinion enhances the construction of DAGs, providing a more robust and realistic representation of the causal model and aiding in identifying appropriate adjustment strategies for epidemiological analysis.

CHAPTER 2

LITERATURE REVIEW

2.1 Introduction

This chapter provides a comprehensive review of cardiovascular diseases and related topics, including methodologies used in this study. The chapter begins with an overview of the definition, classification, and epidemiology of CVDs, followed by an exploration of premature mortality, including its measurement methods and the global and country-specific burdens associated with premature CVD mortality. The chapter then delves into the existing literature on factors associated with CVD mortality. Subsequently, methodologies employed in review studies, such as bibliometric analysis and meta-analysis, are discussed. This is followed by a review of trend analysis techniques and prediction modeling methodologies, with a specific focus on survival modeling. Finally, the chapter provides an overview of causal inference frameworks, specifically addressing the DAG method.

2.2 Cardiovascular diseases

2.2.1 Definition CVD

Cardiovascular diseases or CVD encompasses a broad spectrum of disorders, ranging from conditions affecting the cardiac muscle to those impacting the vascular system that supplies blood to essential organs such as the heart, brain, and other vital organs (Gaziano *et al.*, 2006). In general terms, CVD refers to conditions affecting the heart or blood vessels, often associated with the accumulation of fatty deposits within the arteries (atherosclerosis) and an increased susceptibility to blood clots (WHO, 2021a). CVD stands as one of the four primary non-communicable diseases (or NCDs),

alongside cancers, respiratory diseases, and diabetes (WHO, 2022). NCDs are characterized by conditions that usually progress gradually over time and are not primarily caused by acute infections. Unlike communicable diseases, NCDs are not spread through infection or direct contact with other individuals but are often linked to unhealthy behaviors (PAHO., 2023). These diseases frequently lead to long-term health complications, necessitating ongoing treatment and care. They pose a significant threat to health and development, with NCDs claiming the lives of 41 million people annually, representing 74% of all deaths globally (WHO, 2022).

2.2.2 Main type of CVD

There are several types of CVDs, including: 1) coronary heart disease, which affects the vessels supplying the heart muscle; 2) cerebrovascular disease, impacting vessels supplying the brain; 3) peripheral arterial disease, affecting vessels supplying the arms and legs; 4) rheumatic heart disease, resulting from damage to the heart muscle and valves; 5) congenital heart disease, involving birth defects that affect the heart's development and function; and 6) deep vein thrombosis and pulmonary embolism, entailing blood clots in leg veins that may dislodge and migrate to the heart and lungs (WHO, 2021a). The most common causes of CVD morbidity and mortality are ischemic heart disease and cerebrovascular diseases, or stroke (WHO, 2021b). This review will describe these two main types of CVD.

2.2.2(a) Ischemic heart disease

The term ischemic heart disease or IHD falls within the broader category of coronary heart disease. "Ischemic" denotes a condition where an organ, in this case, the heart, does not receive adequate blood and oxygen supply. Ischemic heart disease specifically refers to heart issues stemming from narrowed coronary arteries, which are responsible for supplying blood to the heart muscle (Institute of Medicine., 2010). It

encompasses a range of clinical syndromes characterized by myocardial ischemia, which signifies an imbalance between the supply of blood to the myocardium (heart muscle) and its demand for oxygen (Steenbergen & Frangogiannis, 2012).

The presentations of IHD vary depending on the duration, severity, and acuteness of the ischemic episodes. Acute coronary syndromes (ACS), a range of clinical conditions including unstable angina, non-ST-elevation myocardial infarction, and ST elevation myocardial infarction, stem from a sudden critical reduction in coronary blood flow. Conversely, in chronic IHD, the presence of coronary lesions that limit blood flow impedes the heart's ability to meet increased myocardial oxygen demands, leading to the development of angina pectoris—a transient discomfort felt in the chest and nearby areas (Steenbergen & Frangogiannis, 2012). The primary two manifestations of IHD are angina and acute myocardial infarction (Gaziano *et al.*, 2006).

2.2.2(b) Stroke

The term "cerebrovascular" consists of two components: "cerebro," pertaining to the large part of the brain, and "vascular," relating to arteries and veins. Together, "cerebrovascular" refers to the blood flow within the brain (AANS., 2024). A stroke, a subtype of cerebrovascular disease also known as a cerebrovascular accident, is an acute medical emergency characterized by a sudden compromise in cerebral perfusion or vasculature (Khaku & Tadi, 2024). It occurs when blood flow to certain areas of the brain is obstructed (ischemic stroke) or when a blood vessel ruptures (hemorrhagic stroke), resulting in damage to brain tissue.

Ischemic strokes, the most common type, account for about 85% of cases (Mozaffarian *et al.*, 2016). Ischemic strokes are classified as thrombotic or embolic. Thrombotic strokes happen when a blood clot obstructs a brain artery, while embolic

strokes occur when plaque or a clot dislodges and blocks a downstream artery (AANS., 2024). Hemorrhagic strokes result from weakened vessel rupture due to factors like high blood pressure, aneurysm rupture, or medication side effects. Intracerebral hemorrhage involves bleeding directly into brain tissue, often forming a clot, while subarachnoid hemorrhage fills the cerebrospinal fluid spaces around the brain, both posing serious risks (AANS., 2024).

Stroke can manifest with various symptoms, including sudden weakness or paralysis on one side of the body, difficulty speaking or understanding speech, and vision problems (Abiodun, 2018). Immediate medical attention is crucial to minimize brain damage and improve outcomes. Treatment options may include clot-busting medications, surgical interventions, and rehabilitation therapies. Prevention strategies include managing risk factors such as high blood pressure, diabetes, and smoking, as well as adopting a healthy lifestyle with regular exercise and a balanced diet (CDC., 2022).

2.2.3 Classification of CVD (codes)

Established by the World Health Organization, the International Statistical Classification of Diseases, 10th revision (ICD-10) serves as the global standard for recording and analyzing information on both mortality and morbidity (illness) statistics across various diseases (National Center for Health Statistics, 2022). ICD-10 can be used to code and classify morbidity data from the inpatient and outpatient records, physician offices, and most National Center for Health Statistics (NCHS) surveys. This standardized system facilitates the efficient storage, retrieval, analysis, and interpretation of health data, enabling meaningful comparisons between different countries. This allows for a comprehensive understanding of global health trends and facilitates informed decision-making in healthcare policies and interventions.

The ICD-10 code range for CVD is I00-I99, encompassing a diverse range of conditions affecting the heart and circulatory system. This includes specific codes for main CVD types: ICD-10 codes I20-I25 for Ischemic heart diseases (e.g., coronary heart disease) and codes I60-I69 for Cerebrovascular diseases (e.g., stroke). For further details on specific codes, refer to **Table 2.1**.

Table 2.1 The International Classification of Diseases, 10th revision (ICD-10) for main CVD

| CVD types | Codes | Disease |
|-----------------------------------|------------|---|
| Ischemic heart diseases | <u>I20</u> | Angina pectoris |
| | <u>I21</u> | Acute myocardial infarction |
| | <u>I22</u> | Subsequent ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction |
| | <u>I23</u> | Certain current complications following ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction (within the 28-day period) |
| | <u>I24</u> | Other acute ischemic heart diseases |
| | <u>I25</u> | Chronic ischemic heart disease |
| Heart failure | I50 | Heart failure |
| Cerebrovascular diseases / Stroke | <u>I60</u> | Nontraumatic subarachnoid hemorrhage |
| | <u>I61</u> | Nontraumatic intracerebral hemorrhage |
| | <u>I62</u> | Other and unspecified nontraumatic intracranial hemorrhage |
| | <u>I63</u> | Cerebral infarction/CVA/stroke |
| | <u>I65</u> | Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction |
| | <u>I66</u> | Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction |
| | <u>I67</u> | Other cerebrovascular diseases |
| | <u>I68</u> | Cerebrovascular disorders in diseases classified elsewhere |
| | <u>I69</u> | Sequelae of cerebrovascular disease |

Source: (National Center for Health Statistics, 2022)

2.2.4 Epidemiology of CVD

2.2.4(a) Incidence, burden, and trend of CVD

Cardiovascular diseases primarily IHD and stroke, are the world's leading cause of death, disability, and premature mortality, as well as a major contributor to rising healthcare costs (Roth *et al.*, 2020; Vos *et al.*, 2020). This burden falls disproportionately on LMICs, where CVD accounts for nearly 80% of global deaths (WHO, 2021a). Since 1990, CVD cases have more than doubled, reaching 523 million in 2019. Similarly, CVD deaths have nearly doubled, reaching 17.8 million in 2017, and years of life lost to disability have significantly increased (Roth *et al.*, 2020).

2.2.4(b) The global burden of IHD

Ischemic heart disease remains a major public health challenge worldwide, claiming over 7 million lives in 2010 alone (American Heart Association., 2020). While improved survival rates for acute myocardial infarction (AMI) have emerged, many individuals live with chronic symptoms associated with stable angina pectoris or ischemic heart failure. Notably, the 2010 Global Burden of Diseases, Injuries, and Risk Factors study employed disability-adjusted life-years (DALYs) to quantify the burden of IHD and other prevalent diseases (Moran *et al.*, 2014). Their findings revealed a complex interplay: despite declining age-adjusted IHD incidence and mortality in most regions, population growth and aging have led to an overall increase in the global burden of IHD since 1990. Interestingly, the study also highlighted that the global IHD burden is primarily driven by fatal IHD with non-fatal IHD contributing less significantly, and acute non-fatal IHD (AMI or unstable angina) having the least impact (Moran *et al.*, 2014).

2.2.4(c) The global burden of stroke

Stroke is the second leading cause of death and the fourth leading cause of disability globally, measured in disability-adjusted life years (WHO, 2008). In 2005, the WHO estimated 5.7 million deaths and 16 million new strokes, leaving an estimated 62 million stroke survivors (Strong, Mathers & Bonita, 2007). By 2030, these numbers are projected to rise to 7.8 million deaths and 23 million new strokes, respectively (WHO, 2008). Though stroke remains a major cause of death in developed countries, LMICs now experience higher rates of first-time strokes compared to HICs, with this trend beginning around 2000 (Feigin *et al.*, 2009).

2.2.4(d) Epidemiological transitions

The global burden of CVD and its risk factors continues to increase due to ongoing epidemiological transitions (Yusuf *et al.*, 2001). Prior to 1900, infectious diseases and malnutrition were leading causes of death. CVD was not as prevalent, with rheumatic heart disease being the main concern, often stemming from infections or malnutrition. As infectious diseases lessened and nutrition improved, a second stage emerged with hypertensive illnesses like hemorrhagic stroke and hypertensive heart disease gaining prominence. Now, in the third stage, longer life expectancy, high-fat diets, smoking, and sedentary lifestyles drive the rise of NCDs. IHD and stroke now dominate mortality rates, especially among those under 50 (Yusuf *et al.*, 2001).

2.3 Premature mortality

2.3.1 Definition

Premature mortality, defined as death occurring before the average age of death within a specific population (National Cancer Institute, 2021b), serves as a pivotal indicator of population health. It reflects the unfulfilled life expectancy, which estimates

the additional years an individual of a certain age can typically anticipate living (Bezy, 2024). However, life expectancy varies significantly across regions, influenced by factors such as sex, age, race, and geographic location. Notably, life expectancy at birth tends to be lower in less-developed countries compared to their more-developed counterparts (Liou *et al.*, 2020).

The term "premature mortality" holds substantial significance in assessing international and country-level performance, aiming to capture aspects of "unnecessary" or "avoidable" mortality burdens. Despite its intuitive appeal and potential policy relevance, the measurement of premature mortality poses challenges due to its latent nature. Consequently, various metrics for premature mortality are currently in use, reflecting the complexity of accurately quantifying this concept.

Calculating the burden of premature mortality involves several methods: (i) assessing the proportion of premature mortality under a chosen age threshold, (ii) determining age-standardized mortality rates within a defined age range, (iii) computing years of life lost (YLL) (Gardner & Sanborn, 1990), (iv) estimating the probability of dying within a specific age range using the life table method (Cullen, Cummins & Fuchs, 2012), and (v) comparing the standardized mortality ratio (SMR) of a study population to that of a reference population (New Mexico's Indicator-Based Information System, 2018). Among these methods, YLL and ASMR stand out as standard parameters, providing a more accurate measurement of premature mortality.

2.3.2 Years of life lost

Years of life lost or YLL is a standard parameter measurement of premature mortality. This indicator accounts for death numbers and the age at which the death occurs, giving more weight to deaths at younger ages (Romeder & Mcwhinnie, 1977;

Gardner & Sanborn, 1990). The method of calculating YLL varies from author to author. In general, two methods are commonly used to calculate YLL: i) years of potential life lost (YPLL) and ii) standard expected years of life lost (SEYLL).

YPLL was first introduced in 1941 for the tuberculosis mortality study (Dempsey, 1947). In 1971, Romeder et al. (Romeder & Mcwhinnie, 1977) refined the method of calculating YPLL as a useful mortality index for health planning, and then in 1990, the formula for YPLL was adopted by Gardner (Gardner & Sanborn, 1990). YPLL was commonly used because it was easy to calculate by subtracting the age of death from a chosen cut-off (e.g., 65, 75, or 85 years) (Gardner & Sanborn, 1990; CDC., 1993). The conventional age threshold measures of YPLL, however, do not account for deaths after the cut-off age, leading them to fail in capturing avoidable deaths at ages outside the selected age range. Furthermore, the selection of the upper age limit varies from study to study.

In 1996, the GBD study introduced SEYLL to address the issue of arbitrary age threshold selection (Murray, 1994). The SEYLL formula is based on comparing the age of death to the standard life expectancy of an individual at each age and incorporates time discounting and age weighting. Consequently, SEYLL is increasingly used as an indicator of premature mortality to calculate the mortality-associated disease burden.

2.3.3 Age standardized mortality rate

Age-standardized mortality rate or ASMR is a commonly used measure to assess premature mortality in a population. ASMR adjusts for differences in the age distribution of populations, which can vary widely between countries or regions (WHO, 2023c). By controlling for these differences, ASMR allows comparisons between populations with different age structures. ASMR can be used to monitor changes in premature mortality over time and to compare mortality rates between different

populations. It is a useful tool for identifying health disparities and evaluating the impact of public health interventions.

The age limit for calculating ASMR for premature mortality varies depending on the individual context and purpose of the analysis. WHO considers an ASMR for premature mortality between the ages of 30 and 69 years (WHO, 2018b), while some studies report an ASMR below 65 (Huisman & Bonneux, 2009) and 75 (Mackenbach *et al.*, 2015).

To calculate ASMR, age-specific mortality rates (i.e., the number of deaths within specific age groups divided by the corresponding population size) are applied to a standard population structure. The standard population structure is usually based on the age distribution of a reference population, such as a national or international standard. The age-specific mortality rates for each age group are then weighted based on the standard population structure, and the weighted rates are summed to obtain the ASMR. The ASMR is then calculated as the ratio of the expected number of deaths to the corresponding standard population size, expressed as a rate per 100,000 or 1,000 population (Naing, 2000a).

In summary, the ASMR calculation entailed two steps (Naing, 2000b): 1) calculate age-specific mortality rates. This involves calculating the number of deaths in each age group and dividing it by the corresponding population size for that age group. The result is the age-specific mortality rate. 2) Apply the standard population structure. The age-specific mortality rates are then multiplied by the corresponding proportion of the standard population in each age group. The ASMR is then calculated as the ratio of the expected number of deaths to the corresponding standard population size, expressed as a rate per 100,000 or 1,000 population. The formula for calculating ASMR is as follows:

$$ASMR = \frac{\Sigma (\text{age specific mortality rate} \times \text{standard population proportion})}{(\text{Standard population size})} \times 100,000$$

where, Σ represents the sum over all age groups.

2.3.4 Global burden of Premature CVD mortality

Premature mortality is a public health problem not just for CVD but for all four major categories of NCDs (CVD, cancer, chronic obstructive lung disease, and diabetes mellitus). They collectively contribute to over 80% of all premature mortality due to NCDs (WHO, 2022). Globally, 17 million premature deaths (under the age of 70) were caused by NCDs where, 38% of that was attributable to CVDs (WHO, 2021a). Furthermore, CVDs in LMICs are significant contributors to the escalating burden of NCDs, accounting for approximately 86% of all premature NCD deaths globally (WHO, 2022).

This premature mortality from NCDs results in loss of productivity and has an impact on the economy. Thus, in 2013, the WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 targeted a 25% reduction in the probability of premature death attributable to NCD by the year 2025 (WHO, 2013). Global and regional benchmarking play an important role to track the progress toward WHO Global Action Plan target. However, it remains unclear how trends in the specific type of CVD vary across population subgroups as well as the associated contributions of specific risk factors to CVD mortality. In 2015, using GBD data, Roth et al. conducted a study to project the global and regional premature cardiovascular mortality in 2025. Their study suggested if the currently observed trends in tobacco use, diabetes mellitus, obesity, and